Clinical Trials
51 trialsNCT02959463 2026-05-27
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04158141 2026-05-19
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Phase 3 Terminated
NCT02399371 2026-05-08
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Phase 2 Completed
NCT03228537 2026-05-01
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01064648 2026-04-29
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03710876 2026-04-21
INFINITE
Ferring Ventures Limited
Phase 3 Completed
NCT02535312 2026-04-17
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03126630 2026-04-01
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT03054298 2025-04-29
CAR T Cells in Mesothelin Expressing Cancers
University of Pennsylvania
Phase 1 Completed
NCT02349412 2025-02-07
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT04843007 2024-10-23
Alvopem® (Pemetrexed) Safety Assessment
NanoAlvand
Completed
NCT01265433 2024-10-09
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Phase 2 Completed
NCT03502746 2024-05-14
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT03399552 2023-10-23
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02709512 2023-10-04
ATOMIC
Polaris Group
Phase 2/3 Completed
NCT02899195 2023-07-05
PrE0505
PrECOG, LLC.
Phase 2 Completed
NCT00101283 2023-07-03
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00738582 2022-09-22
Amatuximab
Morphotek
Phase 2 Completed
NCT02347917 2022-04-12
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Sumitomo Pharma Co., Ltd.
Phase 1/2 Completed
NCT02568449 2021-12-09
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02408016 2021-09-13
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01085630 2021-08-18
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00700336 2021-07-20
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
CanBas Co. Ltd.
Phase 1/2 Completed
NCT00003508 2021-04-27
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Burzynski Research Institute
Phase 2 Terminated
NCT01675765 2020-09-30
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Aduro Biotech, Inc.
Phase 1 Completed
NCT00859495 2020-08-25
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Columbia University
Phase 2 Terminated
NCT02672033 2020-07-24
Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma
Jonsson Comprehensive Cancer Center
Phase NA Terminated
NCT01112293 2020-04-10
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02357147 2020-03-17
ARTEMIS
Morphotek
Phase 2 Terminated
NCT00770120 2020-03-06
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT01098266 2019-09-17
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
AGC Biologics S.p.A.
Phase 3 Completed
NCT03175172 2019-04-04
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Aduro Biotech, Inc.
Phase 2 Terminated
NCT00365053 2018-06-07
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01160458 2018-04-10
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00243074 2018-01-23
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01861301 2016-10-24
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00165503 2016-09-09
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00509041 2016-08-11
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00398138 2016-03-02
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01024946 2015-05-12
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00459862 2015-02-24
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00309946 2014-07-31
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00392444 2014-05-21
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed